Authors
Bercovici, T., Bismuth, M., Goldsmith, M., Peer, D., Ilovitsh, T.
Abstract
Stimulus-responsive nanomedicines promise spatiotemporally controlled therapy, yet most systems rely on passive delivery and lack precise, externally programmable activation while maintaining clinical compatibility. Here we engineer sub-200 nm, perfluorocarbon (PFC)-core nanodroplets (NDs) that integrate efficient core drug loading, physiological stability, and acoustically programmable activation within a single nanoscale agent. These NDs are fabricated using microfluidic nanoassembly to achieve controlled size and composition, and are designed to encapsulate fluorinated payloads directly within the liquid core. Upon exposure to a sequential dual-frequency ultrasound (US) paradigm, the NDs undergo acoustic droplet vaporization followed by low-frequency cavitation, enabling spatially confined mechanical disruption and on-demand payload release within clinically relevant acoustic limits. These properties are engineered to overcome physicochemical barriers in solid tumors, including dense extracellular matrix and restricted drug penetration. This approach achieves enhanced payload release and induces potent mechanochemical cytotoxicity in vitro. In vivo, NDs exhibit prolonged circulation and tumor accumulation, while US activation drives substantial tissue fractionation, control drug release, and increases subsequent nanoparticle uptake. When applied to a solid tumor model, this combined mechanochemical strategy improves tumor control and significantly extends survival compared to either modality alone. These acoustically activatable NDs provide a versatile system for stimulus-responsive, site-targeted drug delivery and mechanical tumor disruption, with strong potential for clinical translation.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 23 Apr 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0